

Measure	Weight	Measure Description	Points earned
#1	10	High Quality Clinical and Physics Data Submission and Completeness¹	
		Four Data Quality Metrics Met	10
		Three Data Quality Metrics Met	8
		Two Data Quality Metrics Met	4
		One Data Quality Metric Met	2
		None of the Data Quality Metrics Met	0
#2	5	Submission of Technical Data (Dose Volume Histogram, DICOM-RT, and Physics Radiotherapy Technical Details Survey)	
		>85% of technical data submitted within six weeks of treatment completion	5
		>85% of technical data submitted within eight weeks	4
		>85% of technical data submitted within twelve weeks	3
		>85% of technical data submitted after twelve weeks	2
		<85% of technical data submitted after twelve weeks	0
#3	20	Collaborative-Wide Measure: Rate of single fraction treatment for uncomplicated² bone metastasis	
		>20% of patients with an uncomplicated bone metastasis are treated with a single fraction	20
		11-20% of patients with an uncomplicated bone metastasis are treated with a single fraction	10
		0-10% of patients with an uncomplicated bone metastasis are treated with a single fraction	0
#4	16	Reduced use of breast boost in women age 70 years or older with early-stage breast cancer³	
		30% or fewer of select patients receive a boost	16
		31-50% of select patients receive a boost	8
		>50% of select patients receive a boost	0
#5	16	For node-negative breast cancer patients, ≥95% of the lumpectomy cavity PTV receives ≥95% of the whole breast prescription dose AND the heart mean dose meets threshold appropriate to laterality and fractionation⁴	
		85% of patients meet target coverage and heart sparing goals	16
		60-84% of patients meet target coverage and heart sparing goals	8
		<60% of patients meet target coverage and heart sparing goals	0
#6	6	Mean heart dose achieved in breast patients receiving conventionally fractionated radiotherapy to supraclavicular, infraclavicular, and/or internal mammary nodes⁵	
		≥85% of patients meet the appropriate threshold	6
		60-84% of patients meet the appropriate threshold	3
		<60% of patients meet the appropriate threshold	0
#7	6	For lung cancer patients, ≥ 95% of the Planning Target Volume (PTV) receives ≥100% of the prescription dose AND the heart mean dose is ≤20 Gray (Gy)	
		≥65% of patients meet target coverage and heart sparing goals	6
		50-64% of patients meet target coverage and heart sparing goals	3
		<50% of patients meet target coverage and heart sparing goals	0

Measure	Weight	Measure Description	Points earned
#8	6	For lung cancer patients: evaluate Task Group-263 compliance for the specified structures (heart, PTV, esophagus, spinal cord or canal, and normal lung) for the initial DICOM entry	
		80% or greater compliance for the specified structures	6
		60-79% compliance for the specified structures	3
		<60% compliance for the specified structures	0
#9	5	Collaborative Meeting Participation – Clinical Champion (<i>per MROQC CC Attendance Policy</i>)	
		All meetings or two meetings with one meeting attended by an acceptable designee	5
		Two meetings	3
		One meeting or none attended	0
#10	5	Collaborative Meeting Participation – Physics Lead (<i>or designee</i>)	
		All meetings	5
		Two meetings	3
		One meeting or none attended	0
#11	5	Collaborative Meeting Participation – Clinical Data Abstractor (<i>CDA or designee</i>)	
		All meetings	5
		Two meetings	3
		One meeting or none attended	0

¹Data Quality Metrics

A. Highly accurate data:

- Overall data accuracy determined by audit of breast, lung, and bone mets data is ≥95%.

B. Sufficient audit preparation and follow-up:

- Audit materials are available for review at the time of audit
- Appropriate staff member (CDA for clinical data audit and physicist or dosimetrist for physics data audit) is in attendance at the audit
- Corrections identified during clinical or physics data audit are made within 2 weeks of the audit date.

C. Active use of data quality reports in the Breast & Lung database

- Fewer than 5% of 2021 patients have a quality report error as of 12/31/21.

D. Active use of data quality reports in the Bone Mets database

- Fewer than 5% of 2021 patients have a quality report error as of 12/31/21.

**2021 patients are defined as patients with an RT end date of 10/1/20-9/30/21 (unless otherwise specified by measure)*

² **Uncomplicated bone mets definition:** No prior radiation to same anatomic site; no cord compression, cauda compression or radicular pain at the site being treated; no prior surgery at the site being treated; no associated soft tissue mass; patient reports any pain (pain score 1-10); intent of treatment: palliation of pain

³ Age ≥70, ER Positive tumors, T1N0/X/M0/X, Grade 1 or 2, Negative (≥2mm) Margins

⁴2021 Breast Cardiac Dose Thresholds (node negative patients):

Conventional: ≤1.7 Gy (left) ≤1 Gy (right)

AWBI (excluding ultra-hypofractionation defined as ≥5Gy/fraction): ≤1.2 Gy (left) ≤.7 Gy (right)

⁵2021 Breast Cardiac Dose Thresholds (node positive patients)

Conventional: ≤2.5 Gy (left) ≤1.3 Gy (right)

Detailed performance measure criteria can be found at www.mroqc.org/members